FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 125 filers reported holding FATE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,488,000 | +350.9% | 25,100 | +560.5% | 0.00% | – |
| Q2 2021 | $330,000 | -94.8% | 3,800 | -94.5% | 0.00% | -100.0% |
| Q4 2020 | $6,332,000 | +363.9% | 69,636 | +103.9% | 0.01% | +350.0% |
| Q3 2020 | $1,365,000 | +118.8% | 34,159 | +7.1% | 0.00% | +100.0% |
| Q4 2019 | $624,000 | +84.1% | 31,900 | +65.3% | 0.00% | 0.0% |
| Q1 2019 | $339,000 | +145.7% | 19,300 | +79.2% | 0.00% | – |
| Q4 2018 | $138,000 | – | 10,770 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |